Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TNYA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTenaya Therapeutics reports Q4 and full year 2025 financial results
Filed March 11, 2026 · Period ending March 11, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release announcing financial results for the quarter and full year ended December 31, 2025. Specific financial figures and operational updates are contained in the attached press release.
Item 2.02 verify on EDGAR → -
low
This is a procedural 8-K filing that formally attaches the earnings press release to the public record. No additional material business events disclosed in the filing body.
8-K: Results of Operations verify on EDGAR →
Summary
Tenaya Therapeutics filed an 8-K to announce its fourth quarter and full year 2025 financial results through a press release dated March 11, 2026. This is a standard quarterly earnings disclosure required for public companies. The actual financial performance metrics, cash position, pipeline updates, and management commentary would be found in the attached press release, which is not detailed in the 8-K body text itself.
For retail investors, the key information to review would be in the press release exhibit, including revenue (if any), operating expenses, cash runway, and any updates on the company's clinical programs. As a clinical-stage biotech, investors should pay particular attention to cash burn rate and runway to determine if additional financing may be needed. Watch for the company's next quarterly update in May 2026 for Q1 2026 results and any interim clinical trial data releases.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On March 11, 2026, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2025
The company disclosed its fourth quarter and full year 2025 financial results through a press release. The actual financial figures and operational details are contained in the attached press release exhibit, which is not included in this 8-K body text.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release of Tenaya Therapeutics, Inc., dated March 11, 2026
The 8-K attaches a press release dated March 11, 2026 as Exhibit 99.1. The filing body provides no details about the press release content, so the nature and materiality of the disclosure cannot be determined from this 8-K alone. This is a procedural filing to formally attach the press release to the public record.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify